TABLE 3.

Timing of pharmacokinetic studies and NFV administration

Characteristic	PK1	PK2	PK3
No. of patients	10	10	4
Age at the time of the study (mo)	2.7 ± 0.8	7.8 ± 2.4	18.3 ± 2.2
Daily dose (mg/kg/day)	136 ± 20	138 ± 19	132 ± 20
No. of patients dosed BID/no. of patients dosed TID	6/4	10/0	4/0
No. of patients who received powder/ no. of patients who received tablets	4/6	1/9	0/4